SecBot SecBot
8-K ·Filed Sep 15, 2026

NRXP

NRX Pharmaceuticals, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001437749-26-030492
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The reclassification reduces regulatory risk and shortens the timeline to a potential November 10, 2026 PDUFA/GDUFA decision. Traders should monitor for FDA action around that date and any subsequent commercial launch updates for NRX-100.

DirectionBullish
Confidencehigh
Horizonweeks

Preservative-Free Ketamine

◆ Mixed Named in this 8-K
Impact
Phase
Approved (ANDA)
Time to market
Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
Next catalyst
None dated

What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.35
T+0 close · Sep 15, 2026 · via day close
Latest settled
−19.40%
T+20 · $2.70 · next T+60 in 23d
Vs SPY
−22.58%
α at T+20
Latest observation
−25.89%
T+41 · FF3 residual α
  1. T+0 · Sep 16 $3.35entry
  2. T+1 · 2mo ago +1.19%α +0.06% · $3.39
  3. T+5 · 8w ago −5.67%α −8.24% · $3.16
  4. T+20 · 5w ago −19.40%α −22.58% · $2.70
  5. T+43 · todayOpen
  6. T+60 · in 23d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from a Major Amendment to a Minor Amendment, pulling the GDUFA goal date forward to November 10, 2026. This regulatory de-escalation signals a lower review burden and accelerates the timeline toward potential approval of a drug-shortage product, a modest but positive catalyst for a clinical-stage biopharma with a $147M market cap.

Key Facts

  • FDA reclassified NRx's ANDA amendment from Major to Minor Amendment.
  • GDUFA goal date revised to November 10, 2026.
  • FDA cited the reclassified amendment will not require a substantial expenditure of resources.
  • Product is preservative-free ketamine (NRX-100), designated a drug shortage product.
  • NRX-100 has Fast Track Designation for suicidal ideation in depression.

Financial Impact

No financial figures provided; regulatory milestone accelerates potential market entry for a drug-shortage product.

Risk Factors

  • FDA may still issue a Complete Response Letter (CRL) at the goal date.
  • Company remains clinical-stage with no approved products; cash runway and commercial execution are unproven.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-030492
Exhibit: ex_1016862.htm0001437749-26-030492
Document: 0001437749-26-030492-index-headers.html0001437749-26-030492
Document: 0001437749-26-030492-index.html0001437749-26-030492
Document: 0001437749-26-030492.txt0001437749-26-030492

Track record

22 reports on NRXP

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Viewing Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 16, 2026